Rifaximin in Patients With Diabetic Gastroparesis

Last updated: October 30, 2025
Sponsor: Mayo Clinic
Overall Status: Terminated

Phase

2

Condition

Diabetic Gastroparesis

Gastroparesis

Treatment

Rifaximin

Placebo

Clinical Study ID

NCT04254549
19-002908
  • Ages 18-75
  • All Genders

Study Summary

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

Eligibility Criteria

Inclusion

Inclusion Criteria

  • Men and women adult patients, aged 18-75, with diabetic gastroparesis

  • Diagnosis of diabetic gastroparesis will have been made previously using a combination of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (GES; > 20% remaining at 4 hours)

Exclusion Criteria

  • Prior surgery to the stomach or esophagus

  • Known mechanical obstruction of the GI tract

  • Current or recent (< 4 weeks) use of opioids

  • Current/active use of cannabis

  • Current or recent (< 4 weeks) use of antibiotics

  • Current or recent use of antifungal agents (< 4 weeks)

  • Prior treatment with rifaximin (< 1 year)

  • Uncontrolled diabetes with a HgbA1c > 12

  • Severe uncontrolled or untreated anxiety or depression.

Study Design

Total Participants: 5
Treatment Group(s): 2
Primary Treatment: Rifaximin
Phase: 2
Study Start date:
June 14, 2019
Estimated Completion Date:
April 11, 2025

Connect with a study center

  • Mayo Clinic in Florida

    Jacksonville, Florida 32224
    United States

    Site Not Available

  • Mayo Clinic in Florida

    Jacksonville 4160021, Florida 4155751 32224
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.